TTrialPathMatch Me to Trials
← Back to trials
RecruitingGlioblastoma Multiforme of BrainGliomaGlioblastoma

A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma

Eligible age

18+ yrs

Accepts

All genders

Locations

4 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is an open-label, multicenter dose-escalation study to be followed by a dose expansion to define the optimal dose of GLIX1 as monotherapy by reviewing safety and tolerability, disease characteristics and pharmacokinetic profiles and preliminary clinical activity in participants with a high grade diffuse glioma that progressed during or recurred after prior standard of care therapies or investigational therapies as clinically indicated. Patients will be treated daily with GLIX1 capsules until disease progression or unacceptable safety.

Sponsor: Tetragon Biosciences Ltd

Where it's recruiting

California

Palo Alto

Florida

Tampa

Illinois

Chicago

New York

New York

Source: ClinicalTrials.gov · NCT07464925 · last updated 2026-11-04